Evidence map›Paper›PMID 40002210›Full record

ArticleCancers2025

Long-Term Outcomes After Multidisciplinary Treatment for Pediatric Orbital Rhabdomyosarcoma.

Nur Khatib, Johannes H M Merks, Jeroen E Markenstein, Brian V Balgobind, Cemile D Savci-Heijink, Michele Morfouace, Bradley R Pieters, Peerooz Saeed

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nur KhatibOrbital Center, Department of Ophthalmology, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0003-2614-5446
Johannes H M MerksPrincess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.ORCID 0000-0001-7659-1028
Jeroen E MarkensteinDepartment of Radiology, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.
Brian V BalgobindDepartment of Radiation Oncology, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.
Cemile D Savci-HeijinkDepartment of Pathology, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.
Michele MorfouacePrincess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Bradley R PietersDepartment of Radiation Oncology, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-7427-8836
Peerooz SaeedOrbital Center, Department of Ophthalmology, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Orbital rhabdomyosarcoma is a rare and aggressive soft tissue tumor that primarily occurs in the eye socket (orbit) of children. Treatment usually involves a combination of surgery, chemotherapy, and radiation therapy, aiming to remove the tumor and prevent metastasis. (2) Methods: An institutional retrospective study was conducted with data from 39 patients with primary orbital RMS treated between 1995 and 2016 at the Amsterdam University Medical Centers/Emma Children Hospital. (3) Results: The median age at presentation was 7 years (range, 9 months to 16 years). The median follow-up period was 9.4 years (range, 3 to 25 years). Ten underwent chemotherapy and excision without additional radiotherapy. A total of 29 patients received additional local treatment: Ablative surgery MOld technique with after loading brachytherapy and surgical REconstruction (AMORE) (N = 21), proton (N = 4) or external beam radiation treatment (EBRT; N = 4). We found 14 cases with recurrences, 9 of which underwent exenteration and two of which died. The 10-year overall survival rate was 95% and the EFS was 63%. (4) Conclusions: long-term follow-up with 10-year survival rate of orbital RMS in this series was 95% achieved by local tumor control and eye preservation in 77% of our study population.

Indexed as

AMORE (mold after loading brachytherapy and surgical reconstruction)orbital tumorspediatric rhabdomyosarcomarhabdomyosarcoma

Identifiers

PMID40002210
PMCPMC11852931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.